| FIALA, Ondrej, Pavel OSTASOV, Petr HOSEK, Ondrej SOREJS, Vaclav LISKA, Tomas BUCHLER, Alexandr POPRACH, Radek KUCERA, Ondrej TOPOLCAN, Jan SUSTR, Monika SEDIVCOVA and Jindrich FINEK. The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. Anticancer Research. Athens: International Institute of Anticancer Research, 2019, vol. 39, No 10, p. 5645-5652. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.13761. |
Other formats:
BibTeX
LaTeX
RIS
@article{1604881,
author = {Fiala, Ondrej and Ostasov, Pavel and Hosek, Petr and Sorejs, Ondrej and Liska, Vaclav and Buchler, Tomas and Poprach, Alexandr and Kucera, Radek and Topolcan, Ondrej and Sustr, Jan and Sedivcova, Monika and Finek, Jindrich},
article_location = {Athens},
article_number = {10},
doi = {http://dx.doi.org/10.21873/anticanres.13761},
keywords = {Primary tumour sidedness; colorectal cancer; cetuximab; panitumumab; bevacizumab},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
title = {The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents},
url = {http://dx.doi.org/10.21873/anticanres.13761},
volume = {39},
year = {2019}
}
TY - JOUR
ID - 1604881
AU - Fiala, Ondrej - Ostasov, Pavel - Hosek, Petr - Sorejs, Ondrej - Liska, Vaclav - Buchler, Tomas - Poprach, Alexandr - Kucera, Radek - Topolcan, Ondrej - Sustr, Jan - Sedivcova, Monika - Finek, Jindrich
PY - 2019
TI - The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
JF - Anticancer Research
VL - 39
IS - 10
SP - 5645-5652
EP - 5645-5652
PB - International Institute of Anticancer Research
SN - 02507005
KW - Primary tumour sidedness
KW - colorectal cancer
KW - cetuximab
KW - panitumumab
KW - bevacizumab
UR - http://dx.doi.org/10.21873/anticanres.13761
L2 - http://dx.doi.org/10.21873/anticanres.13761
N2 - Background/Aim: The aim of our study was to assess the predictive role of primary tumour sidedness (PTS) in patients with metastatic colorectal cancer (mCRC) harbouring wild-type RAS and treated with targeted agents. Patients and Methods: The cohort included 178 patients treated with first-line chemotherapy plus cetuximab, panitumumab or bevacizumab. Results: We observed longer progression-free survival (PFS) and overall survival (OS) in patients with left-sided (L-CRC) compared to right-sided tumours (R-CRC) treated with anti-EGFR mAbs (p=0.0033 and p=0.0037), while there was no difference in patients treated with bevacizumab (p=0.076 and p=0.56). Finally, we observed longer PFS and OS in patients with L-CRC treated with anti-EGFR mAbs and those with R-CRC treated with bevacizumab compared to the reverse combination (p=0.0002 and p=0.011). Conclusion: PTS is a predictive factor for anti-EGFR mAbs, not for bevacizumab. Superior survival was observed when anti-EGFR mAbs were used for L-CRC and bevacizumab for R-CRC.
ER -
FIALA, Ondrej, Pavel OSTASOV, Petr HOSEK, Ondrej SOREJS, Vaclav LISKA, Tomas BUCHLER, Alexandr POPRACH, Radek KUCERA, Ondrej TOPOLCAN, Jan SUSTR, Monika SEDIVCOVA and Jindrich FINEK. The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2019, vol.~39, No~10, p.~5645-5652. ISSN~0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.13761.
|
